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Streptococcus suis is a major swine pathogen, an emerging zoonotic agent responsible
for meningitis, endocarditis and septicaemia followed by deafness in humans. The
development of antimicrobial resistance in S. suis increases the risk for therapeutic failure
in both animals and humans. In this study, we report the synergism of combination
therapy against multi-resistant S. suis isolates from swine. Twelve antibiotic profiles
were determined against 11 S. suis strains. To investigate their synergistic/antagonistic
activity, checkerboard assay was performed for all the possible combinations. In-vitro
killing curves and in-vivo treatment trials were used to confirm the synergistic activity of
special combinations against S. suis dominant clones. In this study, 11 S. suis isolates
were highly resistant to erythromycin, clindamycin, trimethoprim/sulfamethoxazole, and
tetracycline with ratios of 80–100%, and the resistance percentages to enrofloxacin,
florfenicol, and spectinomycin were ∼50%. The checkerboard data identified two
combination regimens, ampicillin plus apramycin and tiamulin plus spectinomycin which
gave the greatest level of synergism against the S. suis strains. In-vitro kill-curves showed
a bacterial reduction of over 3-logCFU with the use of combination treatments, whilst the
application of mono-therapies achieve less than a 2-logCFU cell killing. In-vivo models
confirm that administration of these two combinations significantly reduced the number
of bacterial cells after 24 h of treatment. In conclusions, the combinations of ampicillin
plus apramycin and tiamulin plus spectinomycin showed the greatest synergism andmay
be potential strategies for treatment of multi-resistant S. suis in animal.
Keywords: Streptococcus suis, combination therapy, checkerboard methods, in-vivo mouse model, multiple
resistance
INTRODUCTION
Streptococcus Suis, a facultatively anaerobic Gram-positive coccus, is an important swine pathogen
worldwide and causes considerable economic losses within the swine industry (Haas and Grenier,
2017). S. suis is also known as an emerging zoonotic agent since the first cases of human infection
in 1986 (Perch et al., 1968). In swine, S. suis can cause meningitis, sepsis and arthritis, whereas the
main clinical syndrome in humans is meningitis, followed by septicemia, pneumonia, endocarditis,
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arthritis, and septic shock (Gottschalk et al., 2007; Lun et al., 2007;
Huong et al., 2014; Segura et al., 2017). S. suis can be a commensal
or an opportunistic pathogen and invade pigs through the upper
respiratory-, genital- and alimentary tracts (Nghia et al., 2011;
Segura et al., 2016). Nevertheless humans infections usually occur
via skin lesions (handling of or exposure to infected animals)
or via the oral route (ingestion of contaminated pork-derived
products) (Segura et al., 2016, 2017). Therefore, human disease
mostly occurs occupationally in pig breeders, butchers, pork
processing workers and veterinarians; and consumption of raw or
uncooked pig products is another epidemiology factor of S. suis
infections (Segura et al., 2017).
During the last 20 years, the number of human infections
cases has been dramatically increased, including two outbreaks
in China in 1998 and 2005 (Hu et al., 2000; Yu et al., 2006).
There has also been a growth of morbidity in Thailand and
Vietnam. On the contrary, in Western countries, almost all cases
were sporadic and caused by occupational contact or exposure
to pigs or swine products. Although the majority human cases
were identified in Asian countries (Hui et al., 2005; Yu et al.,
2006; Gottschalk et al., 2007; Nghia et al., 2011), S. suis infections
are reported worldwide, including the United State (Fittipaldi
et al., 2009; Dejace et al., 2017), Australia (Kennedy et al.,
2008), Canada (Gottschalk et al., 2007; Gomez-Torres et al.,
2017), New Zealand (Dickie et al., 1987), and most of Europe
with a highly developed pig industry like The Netherlands, the
United Kingdom (Hernandez-Garcia et al., 2017), France, and
Spain (Goyette-Desjardins et al., 2014; Dutkiewicz et al., 2017).
Between 2002 and 2013, a total of 1,642 S. suis infections were
identified in 34 countries (Goyette-Desjardins et al., 2014); and
in recent years new cases have been first reported occurring
in many other countries, like Malaysia (Rajahram et al., 2017),
Brazil (Doto et al., 2016), Togo (Prince-David et al., 2016), Japan
(Taniyama et al., 2016), and India (Devi et al., 2017). However,
it is noteworthy that the real morbidity of S. suis could be greatly
underestimated due tomisdiagnosis (Bojarska et al., 2016; Callejo
et al., 2016).
Over the past decade, an increasing level of antibiotic
resistance has been reported worldwide, which has been
recognized as a global problem to public health (Hernandez-
Garcia et al., 2017). Notwithstanding, the use of antimicrobial
agents in animals is being strictly monitored, either as
prophylactic, metaphylactic, or therapeutic use, in order to
reduce the medium-long term risk of antimicrobial resistance
in humans. Multidrug-resistant phenotypes of S. suis have
been noted in both pigs and human cases. Penicillin and
cephalosporins are the first choices against S. suis infection,
however resistance to these two drugs was reported in Europe
and China (Shneerson et al., 1980; Zhang et al., 2015).
Tetracycline resistance in S. suis was found in North America,
Asia, and many European countries ranging from 86.9% up
to 100% in pigs (Seitz et al., 2016), and resistance in human
meningitis cases was reported in Asia (Chu et al., 2009; Hoa
et al., 2011). Extensive resistance has been reported against
aminoglysides β-lactams, macrolide, lincosamide, trimethoprim,
and amphenicols (Chu et al., 2009; Holden et al., 2009; Palmieri
et al., 2011; Varela et al., 2013; Huang et al., 2015). Notably,
the bacteria can be commensal or carried in various species,
including birds, rabbits, cats, dogs, horses, cattle, fallow deer,
and wild boars, which may cause widespread in nature and the
persistence of endemic foci in pigs (Hernandez-Garcia et al.,
2017). It is no doubt that S. suis is cause for increasing concern
against the swine industry and human health.
In this work, we try to find prospects to treat multi-drug
resistant S. suis by employing combination therapy. One or two
antimicrobial agents per each category were chosen for this
study, which were conventional and widely used in Chinese
veterinary clinic for treating S. suis diseases. The resistant
characteristics of 11 S. suis isolates from diseased pigs were
tested for MIC as phenotype and confirmed by genotype using
PCR and sequencing. Synergistic interactions between different
antibiotics were investigated against the multiple-resistant S. suis
infection via combination therapy. Then the synergism of certain
combinations was further confirmed by in-vitro and in-vivo
treatment trials.
MATERIALS AND METHODS
Bacteria and Susceptibility Tests
S. suis isolates were collected from diseased or dead pigs at an
animal hospital in Foshan Guangzhou, China, between 2008 and
2013, and were cultured in Tryptical Soy broth or agar plate
(Becton Dickinson Ltd., US) containing 5% defibrinated sheep
blood or 5% new born calf serum (Ruite Bio-tec Company,
Ltd., Guangzhou China) at 37◦C. All isolates were identified
as S. suis by MALDI-TOF/MS (Shimadzu-Biotech). Serotype
was tested by slide agglutination test (Statens Serum Institut,
Copenhagen, Denmark) and PCR test. Twelve conventional
antibiotics, which were commonly used for treatment of S. suis
infections in veterinary clinic, were tested in total for the
minimal inhibitory concentrations (MICs), including ampicillin
(AMP), ceftiofur (CEF), enrofloxacin (ENR), apramycin (AP),
spectinomycin (SPT), tetracycline (TET), erythromycin (ERY),
chloramphenicol (CHL), florfenicol (FFN), tiamulin (TIA),
trimethoprim/sulfamethoxazole (T/S), and clindamycin (CLI).
Broth micro-dilution method was performed in Mueller Hinton
(MH) broth in triplicates regarding the guideline of Clinical and
Laboratory Standards Institute (2013). To confirm the resistant
phenotype, the antimicrobial resistant determinants especially
for erythromycin, clindamycin, and tetracycline were detected by
PCR amplification. In brief, PCR started from 5min of initial
denaturation at 95◦C; followed by 30 cycles of denaturation,
annealing and extension at 95, 50–62, and 72◦C for 45 s, 45 s, and
60 s per kb, respectively; then finished with a final extension at
72◦C for 7min. The positive amplicons were selected randomly
for sequencing analysis (The Beijing Genomics Institute, BGI).
The primers and annealing temperatures were listed in Table S1.
The ATCC 43765 was used as the susceptible control, and 11, 41,
and 1025 were randomly selected for the following experiments
referring the resistant characteristics.
Drug Interaction Assay
The synergistic interaction of all possible combinations
was investigated by checkerboard method using 96-well
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micro-dilution plates. S. suis strains were overnight cultured in
MH broth, washed twice by normal saline and re-suspended
in MH medium, then inoculated to the final cell density of
5×105 CFU/mL. Antibiotics concentrations of 1/8, 1/4, 1/2,
1, 2, 4, and 8 × MIC of each compound were tested. The
combined therapeutic MIC was defined as the concentration of
no visible growth after 24 h incubation at 37◦C. The fractional
inhibitory concentrations index (FICI) for combination effect
was calculated as following:
FICI =
MIC of A in combination
MIC of A alone
+
MIC of B in combination
MIC of B alone
(1)
from which synergism is defined as FICI ≤ 0.5; indifference
was indicated by a 0.5 < FICI≤ 4; and a value of >4 was defined
as antagonistic (Louie et al., 2011).
Killing Curves of Synergistic Combinations
Following overnight incubation at 37◦C, bacterial suspension
was diluted to 106 CFU/ml as an initial inoculum using normal
saline. Working system was composed of a drug-free control,
mono-therapy of drug A and B, and the combination of A and
B together. Concentrations of 1 × MIC and 2 × MIC for every
organism were tested here. Then, 100 µl suspension was sampled
and appropriately diluted for bacterial counting at 0, 3, 6, 9, and
12 h, respectively. Only synergistic combination was estimated
for killing activity against four S. suis strains. A minimum of two
independent experimental runs was performed.
Preliminary Combination Therapeutic
Verification in Vivo
The in-vivo studies were performed on mouse thigh models with
neutropenia. Specific-pathogen-free (SPF) female ICR mice,
aging six-week-old and weighing 25 ± 2 g, were administrated
with cyclophosphamide (Yuanye Biotechnology Co., Ltd,
Shanghai, China) for inducing Neutropenia (neutrophils ≤
100/mm3). An initial dose of 150 mg/kg of cyclophosphamide
was injected intraperitoneally over the first 4 days and followed
by a single dose of 100 mg/kg on the fifth day, prior to thigh
infection.
Then the neutropenic mice were infected with a 100
µl intramuscular injection of exponentially growing bacterial
suspension (107 CFU/mL) into each posterior thigh muscle.
In-vivo treatments with antibiotics or placebo were initiated at 2 h
following the bacterial inoculation. Therapeutic dosages of each
drug were derived from a two-fold MIC value against four S. suis
strains, respectively. In each trial, 16 mice were randomly divided
into four groups and received single administration accordingly,
with PBS as control, drug A as mono-therapy, drug B as
mono-therapy, and A and B together as combination regimen.
Following 24 h of treatment, groups of 4 mice were sacrificed
and thigh homogenates (8 thigh infections) were sampled for
bacterial burden quantification.
Ethics Statement
The SPF female ICR mice were purchased from Hunan
Silaikejingda Lab Animal Ltd., Hunan, China. Groups of four
mice were breeding in SPF environment with a half-half of
light-dark circle in accordance with National Standards for
Laboratory Animals of China (GB 14925–2010). The in-vivo
mouse studies were approved by the Guangdong Association
for Science and Technology [ID: SYXK (Guangdong) 2014–
0136] and the Animal Research Committees of SCAU. All the
protocols were followed the Guangdong Laboratory Animal
Welfare and Ethics guidelines and the Institutional Animal Care




Eight isolates were identified as S. suis serotype 2 strains
(SS2), but the other three were non-typable (Table S2). The
MICs distribution of eleven isolates were shown in Table 1,
where the MIC50 and MIC90 were list as well. In total eleven
isolates were highly resistant to spectinomycin, tetracycline,
trimethoprim/sulfamethoxazole, clindamycin, and erythromycin
with drug resistant percentage of 50% or higher (Figure 1),
referring to the resistance breakpoints (Michigan State University
DCPAH, 2014); but susceptible to ampicillin, ceftiofur, and
tiamulin still. Notably S. suis 1025, 11 and 41 appeared to be
multiple resistant to more than seven different antibiotics (Table
S2). On the other hand, the resistant genes of tetM, lnuB, and
erm(B) were highly distributed in these S. suis isolates with the
detection rates of 72.73, 54.55, and 36.36%, respectively (Table
S3). S. suis 1025, 11 and 41 were found harboring erm(B), tetM,
tetO, tetL, and lnuB genes at the same time, which confirmed
the co-resistance to erythromycin, tetracycline and clindamycin
(Table 1, Tables S2, S3, and Figure S1). Another methylase
gene erm(A) and aminoglycoside-resistant gene aph3′ were
found in isolates 41 and 11. The genotypes inferred from PCR
amplification were excellently matched the resistant phenotypes
as tested by MIC.
Synergism Assay
Based on checkerboard data, an independent interaction (FICI,
ranging from 1 to 3) was shown by most of the possible
combinations against S. suis ATCC 43765 (Table 2). Two
combination regimens of AMP plus AP and TIA plus SPT
scored an FICI of 0.5 and exhibited synergistic antibacterial
effectiveness. Similar results were found in a further test of
these two synergistic combinations against S. suis 1025, 11, and
41 isolates. It was notable that combination administration of
these two groups helped decrease antimicrobial susceptibility
of both drugs. As shown in Table 3, when AMP and AP were
used together, MICs of combined therapy were two- to four-
fold lower than AMP used alone, and vice versa AP MICs also
decreased two- to four-fold together with AMP. Similarly, in
TIA/SPT group, organisms were four times more sensitive to
TIA in the presence of SPT, notwithstanding that they were
basically resistant to SPT (Table 1). On the other way, SPT MICs
in combination with TIA fell back into the intermediate zone
against all three pathogens. Interestingly, the FICI values of both
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TABLE 1 | Distribution of minimum inhibitory concentrations in 11 Streptococcus suis isolates.
Antimicrobial agents MIC distribution by the number of isolates (mg/L) MIC50 MIC90 Resistant breakpoints*
≦0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 ≧128
Ceftiofur 1 2 1 2 2 3 0 0 0 0 0 0 0.5 2 ≧8
Tiamulin 0 0 0 3 4 2 0 0 2 0 0 0 1 16 ≧32a
Ampicillin 7 2 0 0 1 0 0 0 0 1 0 0 0.06 1 ≧2
Apramycin 0 0 0 0 0 0 0 3 2 1 3 2 32 ≧128 NAc
Chloramphenicol 0 0 0 0 2 2 1 3 2 1 0 0 8 16 ≧16
Enrofloxacin 0 1 1 1 3 1 0 2 2 0 0 0 1 16 ≧2
Florfenicol 0 0 0 0 2 1 3 2 1 2 0 0 4 32 ≧8
Spectinomycin 0 0 0 0 0 0 0 0 0 1 3 7 128 256 ≧128b
Tetracycline 0 0 1 1 0 0 0 1 0 4 3 1 32 64 ≧2
Trimethoprim/Sulfamethoxazole 0 0 0 1 0 0 0 0 0 2 2 6 64/1216 64/1216 ≧4/76
Clindamycin 1 0 0 0 0 3 2 1 0 1 1 2 4 128 ≧1
Erythromycin 0 0 0 0 0 0 1 4 1 2 0 3 32 ≧128 ≧1
*Resistant breakpoint data is provided referring to the Resistance Breakpoints for Antimicrobials Used in Animals from Diagnostic Center for Population and Animal Health, Michigan
State University, which is summarised from the CLSI documents Performance Standards for Antimicrobial Susceptibility Testing (M100-S24) and (VET01-S2).
aFor Actinocacillus pleuropneumoniae; bFor bovine respiratory disease; cNA, not applicable; Red vertical line for breakpoints. Bold value represents the number of strains.
FIGURE 1 | Bar chart shows the resistance ratio of S. suis isolates to 12
antimicrobial agents. AMP, Ampicillin; AP, Apramycin; CEF, Ceftiofur; CHL,
Chloramphenicol; CLI, Clindamycin; ENR, Enrofloxacin; ERY, Erythromycin;
FFN, Florfenicol; SPT, spectinomycin; S/T, Compound Sulfamethoxazole; TET,
Tetracycline; TIA Tiamulin. *Two isolates with apramycin MIC of 256µg/ml
were deemed as resistant strains, as no applicable breakpoint for apramycin.
groups against S. suis 1025 were somehow a little higher than the
definition of synergy action, as well as AMP/AP against S. suis 41.
In-Vitro Synergism of AMP/AP and TIA/SPT
In Figure 2, killing activity of antibiotics alone was very limited
even against the S. suis ATCC 43765. However bacterial
reductions of 5–6 logCFU were observed in combined treatment
with AMP/AP and TIA/SPT against isolate 1025. Similar
outcomes were found in groups of TIA/SPT against S. suis
11. But when dealing with S. suis 41, only bacteriostatic effect
was observed regardless of the drug combination. Notably, after
bacterial suspension reaching the plateau stage, a downward
trend was observed in all the control arms (Because of which,
plots at 24 h of the control arms were not shown).
In-Vivo Therapy Verification
Data of in-vivo synergistic treatment are displayed in Figure 3.
Groups of combination therapy generated significant bacterial
killing (Two-tail t-test; dataset comparisons with differences of
P-values of <0.05 were considered to be statistically significant).
Significant synergism of both combinations was observed
when treating against reference strain ATCC 43765 (P < 0.001).
As expected, wild type strains showed stronger viability than
the reference strain, even though reproduction of bacteria had
been inhibited following combination therapy. AP of 512 mg/kg
plus AMP of 64 mg/kg restrained the growth of S. suis 1025
to ∼2-logCFU/g, which was lower than that of mono-therapy
at 24 h (P < 0.05). Similarly, AP/AMP combined treatment
was effective against the infections induced by the other two
pathogens even when administrated with lower doses (P <
0.001). Following administration of TIA plus SPT, there was a
remarkable inhibition of bacterial growth observed in the mouse
thighs infected with S. suis 41 and 11 (P < 0.05 and P < 0.001,
respectively). However, significant difference of bacterial density
was observed only between the assembly of SPT alone and that of
SPT/TIA against S. suis 1025 (P < 0.05).
DISCUSSION
In this study, 8 of 11 isolates were identified as serotype 2 in
the percentage of 72.73%, which suggested that in the Foshan
area serotype 2 might be the most popular serotype in S. suis. In
addition, S. suis serotype 2 was mainly responsible for those two
large outbreaks in China in 1998 and 2005 (Hu et al., 2000; Yu
et al., 2006). So far, over 20 countries and∼700 human cases have
been reported, which were caused by the highly virulent serotype
2 S. suis (Mai et al., 2008; Holden et al., 2009). In humans, it causes
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TABLE 2 | In vitro interactions of 12 antibiotics against S. suis ATCC 43765 calculated by checkerboard method.
Checkerboard AP CHL ENR FFN TIA ERY CLI AMP TET S/T CEF SPT
Apramycin I I I I I I S I I I I
Chloramphenicol 2 I I I I I I I I I I
Enrofloxacin 1.5/2 2 I I I I I I I I I
Florfenicol 2 1.5 2 I I I I I I I I
Tiamulin 2 2 2 2 I I I I I I S
Erythromycin 2 2 2 2 0.75/1 I I I I I I
Clindamycin 1/2 2 2 2 2 2 I I I I I
Ampicillin 0.5 2 0.75 2/3 2 2 1.5/2 I I I I
Tetracycline 2 2 2 2 1.5/2 1.5/2 2 2 I I I
Trimethoprim/Sulfamethoxazole 1.5/2.5 2 1/2 1.5/2 2 2 2 2 2/3 I I
Ceftiofur 1/2 2 0.75/1 2 1.5/2 1.5/2 2 1/1.5 2 1.5/2 I
Spectinomycin 2 2 1.5 2 0.5 2 2 2 2 2 2
FICI, Fractional inhibitory concentration index; S, Synergistic (FICI≤0.5); I, independent (0.5<FICI≤4); A, Antagonistic (FICI>4).
TABLE 3 | Combination MICs and FICI values of AMP/AP and SPT/TIA against S. suis ATCC 43765, 1025, 41, and 11 strains, determined from checkerboard tests.
Strain MIC µg/mL FICI MIC µg/mL FICI








ATCC 43765 0.03 32 0.0075 8 0.5 32 1 8 0.25 0.5
1025 32 256 16 64 0.75 128 16 64 4 0.75
41 0.0625 8 0.031 4 1 256 0.5 64 0.125 0.5
11 0.125 8 0.031 2 0.5 256 16 64 4 0.5
severe health problems including meningitis and septicemia
shock, which may prolong the treatment. Certainly, S. suis
serotype 2 strains are the most prevalent responsible for both
swine and human diseases, among the total 35 serotypes that have
been described during the last decades.
Increasing attention has been paid to S. suis, not only
because of its role in severe infectious cases in humans,
but also due to its involvement in antimicrobial resistance
caused by the abuse of antibiotics (Palmieri et al., 2011; Varela
et al., 2013). In this study, S. suis isolates were resistant
to erythromycin, clindamycin, trimethoprim/sulfamethoxazole,
and tetracycline with resistant percentage over 80% to 100%, and
showed decreasing susceptibilities to enrofloxacin, florfenicol,
and spectinomycin with resistant frequency ∼50% (Figure 1).
Besides, high MICs of apramycin were observed despite there
is no definition of apramycin breakpoint neither from CLSI
nor EUCAST. Although all the isolates were resistant to
erythromycin, extremely higher MICs of over 256 mg/L were
observed in S. suis 1025, 11, and 41 strains and followed by
MIC of 64 mg/L in isolates 114 and NJ-5 (Table S2). As a
predominant resistant mechanism, the presence of ribosomal
methylase genes ermA and/or ermB might be the reason causing
highly resistant phenotype to erythromycin (Table S3), and, less
frequently, harboring the eﬄux pump genes mefA and msrD
(only in isolate 114) could mediate a medium level resistant
to erythromycin. Although there are many genes mediating
tetracycline resistance, the ribosomal protection genes of tetM
and tetO were notably detectable in S. suis and a reduced
frequency to eﬄux gene tetL (Roberts, 2005; Huang et al.,
2015). In agreement with previous reports (Zhang et al., 2015),
highly prevalence of tetM (8 of 11 isolates) and followed by
tetO (three isolates) were detected in this study. However,
detection of eﬄux gene tetL were also observed in S. suis 1025,
11, and 41 strains. The lnuA and lnuB gene are members
of lnu gene family encoding lincosamide nucleotidyltransferase
enzymes, then further causing the resistant to lincosamides
(Montilla et al., 2014). Six from 11 isolates were detected
with lnuB gene, among which two isolates were also harboring
the lnuA gene. Isolates, 2015, 11, and 41, were identified as
multiple resistant S. suis strains based on both phenotype
of the MIC value and genotype of co-existing of different
resistant genes. For these three, antimicrobial resistant genes
of ermB, tetM, tetO, tetL, and lnuB were co-existing, and
the 11 and 41 were also carrying the aph3′ gene mediating
aminoglycosides resistance. It is revealed that resistant genes
to erythromycin, tetracycline, and clindamycin were highly
prevalent in S. suis isolates singly or in combination with each
other.
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FIGURE 2 | In-vitro time-killing curves of synergistic combination against four S. suis strains including ATCC 43765, 1025, 41 and 11. Symbols represent means and
error bars are standard deviations (n = 3).
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FIGURE 3 | Bacteria density in mouse thigh muscles (logCFU/g) after 24 h of monotherapy or combination therapy using different synergistic regimens against four S.
suis strains. Combinations of ampicillin plus apramycin and tiamulin plus spectinomycin were tested against four S. suis isolates. Significant difference was shown as
* and *** representing P < 0.05 and P < 0.001, respectively. AMP, ampicillin; AP, apramycin; TIA, tiamulin; SPT, spectinomycin. (A,B) Show the data for ATCC 43765;
(C,D) for S. suis 1025; (E,F) for S. suis 41; (G,H) for S. suis 11.
By the way, chloramphenicol MICs over 16 mg/L were
observed against S. suis 1025, 11, and 41. However, no detection
of cfr gene (conferring resistance phenicols, lincosamides,
oxazolidinones, pleuromutilins, and streptogramin) were
observed in these strains, inconsistently with previous report
that cfr gene was found in S. suis isolates from porcine in China
(Wang et al., 2013). However, the resistance to chloramphenicol
might be caused by other mechanisms, for example, by cat
genes encoding chloramphenicol acetyltransferase; or genetic
mutation. Similar results were also observed in MICs of
spectinomycin, of which most isolates are resistant, but lack
of the presence of resistant genes. Interestingly, high value of
spectinomycin MICs were found in isolates 11 and 41, however,
as in the same group with spectinomycin, apramycin MICs
against those strains were observed oppositely in a quite low
level. In this study, only few groups of antimicrobial resistant
genes were detected, which might be not sufficient to explain
the all the resistant phenotypes. Besides, under the antimicrobial
selection pressure, excepting for acquiring resistant genes,
S. suis can also survive by other resistant mechanisms, like
up-regulating the express of eﬄux pump, developing tolerance
to antibiotics, or forming biofilms.
In brief, S. suis can be an abundant antibiotic resistance
reservoir contributing to the spread of resistance genes between
animal and human (Palmieri et al., 2011), and it is important to
introduce an effective strategy to treat multiple resistant S. suis.
In this work, 12 antimicrobial agents were tested for synergism
using checkerboard trials, and surprisingly two combinations
of ampicillin plus apramycin and spectinomycin plus tiamulin
emerged to be synergistically effective (FICI of 0.5) against S. suis
ATCC43765 (Table 2). A floating FICI value was observed from
the following checkerboard tests against the clinical isolates 1025,
11 and 41. A FICI of 0.75 for ampicillin plus apramycin against
1025 may be due to MICs of 1025 to ampicillin and apramycin
were extremely higher than other strains, and 1025 is the only
isolates which resistant to ampicillin (Table S2). However, MICs
cannot explain the higher FICIs of 0.75–1 in combination of
ampicillin plus apramycin against strain 41 and spectinomycin
plus tiamulin against 1025, respectively. The synergism was
investigated by in-vitro dynamic killing curves (Figure 2) as well,
from which the conspicuous synergistic killing activity (more
than 3-logCFU/ml reduction) was observed in both combined
strategies. Exceptionally, neither tiamulin and spectinomycin
alone nor combined together could inhibit the growth of S. suis 41
in-vitro. On the other hand, interestingly, decreased cell density
was observed in all the growth curves after bacterial density began
reaching stable status in broth medium, which may be due to
nutritional deficiency and large population density.
Further confirmation on the antimicrobial activity of these
two combination therapies were carried on in-vivo mouse
model. Before treatment, these four strains were colonizing well
in the mouse thigh as expected. In Figure 3, bacterial cells
multiplied to ∼10-log10CFU/g at 24 h after inoculation, which
wasmore viable and virulent than the in-vitro brothmedium. The
combined-therapeutic effectiveness was significantly (P < 0.05,
or P < 0.001) more superior than mono-therapy for both
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pairs of combination for the four S. suis strains. Differences
of 2–5 logCFU/g were achieved between control groups
and the combined treatment groups, and differences of 2–4
logCFU/g were observed between mono-administration and the
combination therapies. Nonetheless only 1-logCFU/g drop of
bacterial counts was shown in spectinomycin combined tiamulin,
which was still significantly decreased than monotherapy against
isolate 1025 (P < 0.5).
However, we noticed there were some shorts for this
study. First, only three multiple-resistant S. suis has been
detected and tested for combination therapies, which might
be insufficient to comprehensively understand the effectiveness
of combined therapy. In addition, preliminary guidance for
rational combination therapy was provided by synergy studies
in mice, which may exert optimum microbiological outcomes.
Nevertheless, since the complicated in-vivo condition, like
dynamic drug concentrations in target tissue, bacterial virulence
and host immune response in different species, cannot be
completely mimicked by mouse model. Outcomes from mouse
model may not be applied in the clinic directly. For instance,
the dosages used in mouse trials were simply extrapolated
from two-fold from the MIC value against each pathogen,
which were not applicable for clinical treatment. Besides, it is
a single administration used for in-vivo treatment in mouse
models during a 24-h treatment. For the combination of
ampicillin plus apramycin, ampicillin is belonging to a time-
dependent beta-lactams antibiotic with none or short post-
antimicrobial effects, and apramycin belongs to aminoglycosides
which is concentration dependent. Based on these different
pharmacokinetic and pharmacodynamic characteristics, it is
recommended that ampicillin might be administrated multiple
times daily in contrast to a single dosing of apramycin. As
to tiamulin combined with spectinomycin, AUC/MIC is the
most reasonable parameter available to the pharmacokinetics
and pharmacodynamics profile (Craig, 1998; Xiao et al., 2016),
therefore single daily dosages might be appropriate. However,
previous report reveals that valnemulin, another pleuromutilin
antibiotic, has shown a better efficacy with spilt dosages than
single administration (Zhao et al., 2014).
Synergism of ampicillin plus apramycin is probably due to the
increased permeation of aminoglycosides into cytoplasm after
beta-lactams inhibiting the cell-wall synthesize by binding with
penicillin binding proteins (PBPs). According to this hypothesis,
penicillin has the ability to lower the MICs of aminoglycosides,
and in which case penicillin may be administrated prior to
aminoglycosides (Costa and Botta, 1984). Interestingly, we also
found a decrease in the value of ampicillin MICs combined
with apramycin (Table 3), however the mechanism remains
unclear. Reports on the synergism of tiamulin combined with
spectinomycin are even more limited. It seems like both of
them are acting on bacterial ribosome and blocking the synthesis
of the 30S protein. Combination therapy of tiamulin plus
spectinomycin may be an appealing option for retaining the
clinical utility of spectinomycin against such resistant strains.
“Maximize therapeutic efficacy while minimizing bacterial
resistance” is the main goal of using of antimicrobials in
both clinical and agriculture (Varela et al., 2013). In clinical,
timely and prudent use of antimicrobial agents may be the
best shot to reduce the impact and spread of antimicrobial-
resistant pathogens for treating of S. suis infection in human.
On the contrary, due to the consideration of public health, not
many choices are left for veterinary S. suis diseases especially
for resistant organisms. Strategies to cut down the impact
of S. suis diseases and the dissemination of antimicrobial
resistance should be focused on improving the management
and environment of swine farming, together with strategic
medication of clinically diseased animals (Varela et al., 2013).
In current study, it was focused on the veterinary antimicrobial
agent only. However, considering S. suis is an opportunistic and
zoonotic pathogen, further study and verification of combining
p0enicillins with aminoglycosides should be studied especially
for human antimicrobial agents. A combination of pleuromutilin
plus aminoglycosides may only be applicable to veterinary use,
since retapamulin is the only pleuromutilin agent approved by
the FDA for external use against Staphylococcus aureus infection
in human clinics.
In summary, we found two combinations, ampicillin plus
apramycin and tiamulin plus spectinomycin, both offering a
substantially strengthened and more synergistic antibacterial
activity against multi-resistant S. suis strains from porcine.
Hopefully, our findings might also shine light on alternative
combination therapies for human infection caused by porcine
streptococcosis.
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